CNSP stock news
This page provides real-time market news, earnings updates, and company announcements related to CNS Pharmaceuticals, Inc. (CNSP).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-14 15:19 EST
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Finviz2026-03-08 22:03:39
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Finviz2026-03-08 22:03:39
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Finviz2026-03-09 11:03:50
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
Finviz2026-03-09 20:37:28
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-10 11:07:14
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Finviz2026-03-10 20:03:45
Skye Bioscience’s 2025 Q4 Call: ENHANZE Readiness, Dose Selection, and Delivery Method Claims Clash
101 finance2026-03-10 23:00:59
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade
Finviz2026-03-11 01:51:41
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Finviz2026-03-11 11:03:52
SCIENTURE Broadens Commercial Access for REZENOPY, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
Finviz2026-03-11 12:09:49
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Finviz2026-03-11 12:43:08
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Finviz2026-03-11 13:03:51
JHG vs. CNS: Which Stock Offers Superior Value?
101 finance2026-03-11 16:46:16
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Finviz2026-03-12 11:03:48
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Finviz2026-03-12 11:03:49
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Finviz2026-03-12 12:00:47
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Finviz2026-03-12 12:03:53
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 12:03:53
SAGT to Acquire 60% Majority Stake in Fast-Growing F&B Chain Malaya Heritage, Expanding Revenue Base and Entering the Multi-Billion Global Restaurant Industry
Finviz2026-03-12 15:33:10
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide Commercial Rollout
Finviz2026-03-12 20:18:06
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
Finviz2026-03-13 13:03:11
AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold?
101 finance2026-03-13 16:46:36
AXSM's Projected Revenue Growth for 2025 Primarily Attributed to Auvelity: What Lies Ahead?
101 finance2026-03-13 16:46:36
Palantir's Stock Dips Amid Defense AI Expansion and Geopolitical Tensions, Remains 11th Most Actively Traded
101 finance2026-03-13 22:18:40
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-10 11:07:14
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Finviz2026-03-10 20:03:45
Skye Bioscience’s 2025 Q4 Call: ENHANZE Readiness, Dose Selection, and Delivery Method Claims Clash
101 finance2026-03-10 23:00:59
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade
Finviz2026-03-11 01:51:41
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Finviz2026-03-11 11:03:52
SCIENTURE Broadens Commercial Access for REZENOPY, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
Finviz2026-03-11 12:09:49
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Finviz2026-03-11 12:43:08
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Finviz2026-03-11 13:03:51
JHG vs. CNS: Which Stock Offers Superior Value?
101 finance2026-03-11 16:46:16
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Finviz2026-03-12 11:03:48
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Finviz2026-03-12 11:03:49
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Finviz2026-03-12 12:00:47
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Finviz2026-03-12 12:03:53
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-12 12:03:53
SAGT to Acquire 60% Majority Stake in Fast-Growing F&B Chain Malaya Heritage, Expanding Revenue Base and Entering the Multi-Billion Global Restaurant Industry
Finviz2026-03-12 15:33:10
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide Commercial Rollout
Finviz2026-03-12 20:18:06
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
Finviz2026-03-13 13:03:11
AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold?
101 finance2026-03-13 16:46:36
AXSM's Projected Revenue Growth for 2025 Primarily Attributed to Auvelity: What Lies Ahead?
101 finance2026-03-13 16:46:36
Palantir's Stock Dips Amid Defense AI Expansion and Geopolitical Tensions, Remains 11th Most Actively Traded
101 finance2026-03-13 22:18:40
CNSP stock chart
CNSP stock detailsCNSP stock price change
On the last trading day, CNSP stock closed at 2.84 USD, with a price change of -4.05% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more